Compound: nadolol
SMILES: O(c1c2c(ccc1)C[C@@H](O)[C@H](C2)O)CC(O)CNC(C)(C)C
InChIKey: VWPOSFSPZNDTMJ-UCWKZMIHSA-N
Synonyms: nadolol, Corgard, 42200-33-9, Solgol, (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol, SQ-11725, (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol, Anabet, Corzide component nadolol, Nadololum, DTXSID3023342, FEN504330V, NSC-758430, Nadolol [USP MONOGRAPH], 1-(tert-Butylamino)-3-((5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy)-2-propanol, 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, cis-, cis-5-(3-((1,1-Dimethylethyl)amino)-2-hydroxy-propoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol, Nadolol (USP MONOGRAPH), 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, 1-(tert-butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy]-2-propanol, SQ11725, nadololo, 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-, RefChem:55685, CHEBI:7444, C07AA12, DTXCID40209297, 255-706-3, 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol, SQ 11725, Nadolol [MI], Nadolol [HSDB], Nadolol [INN], Nadolol [JAN], Nadolol [USAN], Nadolol [VANDF], Nadolol [MART.], Nadolol [WHO-DD], 1164498-31-0, Nadolol [ORANGE BOOK], MLS000028580, MFCD00079476, 1403-22-1, SMR000058975, Corgard;Solgol, DTXCID903342, SR-01000000251, UNII-FEN504330V, Nadolol CRS, NCGC00016851-01, 220045-89-6, Prestwick_108, Nadolol [EP], Nadolol [USP], CAS-42200-33-9, Nadolol [USP-RS], Spectrum_001643, Opera_ID_1099, Prestwick0_000818, Prestwick1_000818, Prestwick2_000818, Spectrum2_001546, Spectrum3_001586, Spectrum4_000193, Spectrum5_001255, CHEMBL649, SCHEMBL4177, Nadolol component of corzide, Nadolol, analytical standard, BSPBio_003152, GTPL554, KBioGR_000765, KBioSS_002123, cid_39147, MLS001148087, MLS002548875, DivK1c_000427, Nadolol (JP18/USP/INN), NADOLOL [EP IMPURITY], SPECTRUM1503260, SPBio_001392, SPBio_002636, NADOLOL [EP MONOGRAPH], INV102, Nadolol 1.0 mg/ml in Methanol, SCHEMBL29687486, BDBM25766, HMS501F09, KBio1_000427, KBio2_002123, KBio2_004691, KBio2_007259, KBio3_002652, INV-102, NINDS_000427, HMS1570D17, HMS1922O05, HMS2093A15, HMS2233E12, HMS3259C07, HMS3714D17, Pharmakon1600-01503260, MSK10064, Nadolol [USAN:INN:JAN:WHO-DD], Tox21_110646, CCG-39324, EBC-26725, MFCD00082534, NSC758430, s5023, AKOS015895037, Tox21_110646_1, DB01203, FN26118, NC00464, IDI1_000427, SMP1_000203, NCGC00021623-03, NCGC00021623-05, NCGC00089811-02, (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol, SBI-0051806.P002, NS00000501, EN300-50860, VU0239635-6, A12516, D00432, AB00052338_13, Q424952, SR-01000000251-2, SR-01000000251-3, BRD-A87606379-001-03-4, BRD-A87606379-001-13-3, BRD-A87606379-001-22-4, BRD-A87606379-001-23-2, Nadolol, European Pharmacopoeia (EP) Reference Standard, Z608060832, Nadolol, United States Pharmacopeia (USP) Reference Standard, (2R,3S)-5-[3-(tert-butylamino)-2-hydroxy-propoxy]tetralin-2,3-diol
Theoretical properties:
molecular_formula: C17H27NO4
molecular_weight: 309.4 g/mol
exact_mass: 309.19400834 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 6
heavy_atom_count: 22
topological_polar_surface_area: 82 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White to off-white, crystalline powder
color: White to off-white, crystalline powder
odor: Odorless
melting_point: 124-130
Descriptions:
chebi: An aromatic ether, being the (2<i>R</i>)-3-(<em>tert</em>-butylamino)-2-hydroxypropyl ether of the phenolic hydroxy group of (6<i>R</i>,7<i>S</i>)-5,6,7,8-tetrahydronaphthalene-1,6,7-triol.
wikipedia: Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally.
Common side effects include dizziness, feeling tired, a slow heart rate, and Raynaud syndrome. Serious side effects may include heart failure and bronchospasm. Its use in pregnancy and breastfeeding is of unclear safety. It is a non-selective beta blocker and works by blocking β1-adrenergic receptors in the heart and β2-adrenergic receptors in blood vessels.
Nadolol was patented in 1970 and came into medical use in 1978. It is available as a generic medication. In 2020, it was the 340th most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.